BIOSTEM TECHNOLOGIES NEW - BSEM STOCK NEWS

BioStem Technologies (OTC: BSEM) revealed its Q3 2022 financials, reporting net revenue of $1.145 million, a 13% decline from Q3 2021. Despite this, the gross profit margin improved to 74%, up from 59% last year, yielding a gross profit of $0.843 million. The net loss widened to $1.742 million compared to a loss of $0.622 million in the same period last year. Notably, the company is expanding its direct sales force and has added three new Medicare Administrative Contractors, increasing its market coverage to 50% of the U.S. The leadership team also experienced changes, including the appointment of a new CFO.

BioStem Technologies Inc. (OTC: BSEM), a regenerative medicine company, announced a conference call for November 15, 2022, at 4:30 pm EST to discuss its financial results for the quarter ending September 30, 2022. The call will include a corporate update and will be available via webcast. BioStem focuses on placental-derived biologics, utilizing its proprietary BioRetain® processing method. The company operates under strict quality management and is accredited by the American Association of Tissue Banks, ensuring compliance with industry standards.

BioStem Technologies Inc. (OTC PINK: BSEM) has appointed Michael Fortunato, CPA, as Chief Financial Officer, transitioning from his role as Controller. Fortunato brings over 28 years of experience in financial accounting, SEC reporting, and IPOs, notably participating in Alibaba's $22 billion IPO. CEO Jason Matuszewski highlights this as a pivotal moment for the company, emphasizing Fortunato's expertise in advancing BioStem's mission in wound care. The company is engaged in developing placental-derived tissue allografts using its proprietary BioRetain® method.

BioStem Technologies Inc. (OTC PINK: BSEM) announced that CEO Jason Matuszewski will present at the Dawson James Securities 2022 Small Cap Growth Conference on October 12, 2022, from 1:30-1:55 PM EDT. The event will take place in the Preserve Ballroom B. Management will also hold one-on-one meetings with investors throughout the conference. A live webcast of the presentation will be available, along with an archived recording accessible for 90 days on the company’s website. BioStem focuses on regenerative medicine, particularly placental-derived tissue allografts.

BioStem Technologies (OTC: BSEM) announced a guidance paper on growth factor standardization published in Health Science Reports. The paper highlights a new method to quantify growth factors in its Vendaje® and Vendaje AC® allografts, emphasizing the inadequacy of current reporting methods. The proprietary BioRetain® processing method retains the integrity of placental tissues and their growth factors. The CEO stated the commitment to advancing knowledge in wound care, while the R&D VP noted the significance of growth factor standardization for assessing product efficacy.

BioStem Technologies Inc. (OTC: BSEM) announced the appointment of Brandon Poe as an Independent Board Member and Chair of the Audit Committee as of September 7, 2022. CEO Jason Matuszewski emphasized Poe's extensive leadership experience in the biotech sector, expecting his insights to enhance their financial and regulatory frameworks. Poe brings over 25 years of financial experience from companies like Jumpcode Genomics and Illumina. The company aims to leverage his expertise to expand sales capabilities and product offerings in regenerative medicine.

BioStem Technologies (OTC: BSEM) reported strong financial results for Q2 2022, with net revenue of $2.158 million, marking a 133% increase year-over-year. The company achieved a gross profit of $1.773 million, an 82% margin, up from 52% in Q2 2021. Net income improved to $0.203 million, compared to a loss of $0.372 million last year. Year-to-date, revenues reached $4.936 million, up 173%. However, net losses increased to $0.654 million. The company is transitioning to a direct salesforce and expanding its product offerings in advanced wound care.

BioStem Technologies (OTC: BSEM) will host a conference call to discuss its financial results for Q2 2022 on August 22, 2022, at 4:30 PM EDT. The company specializes in regenerative medicine with a focus on placental derived biologics. BioStem's proprietary BioRetain® processing method is key to its product development. The conference call will be available via webcast, with questions submitted online only. BioStem has faced significant losses since inception and may incur future losses, which are potential areas of concern for investors.

BioStem Technologies (OTC: BSEM) was featured on Benzinga's All Access show on June 17, 2022, at 10:20 AM EST. CEO Jason Matuszewski provided updates on the company's business growth and product portfolio. BioStem Technologies focuses on perinatal tissue's regenerative properties, utilizing the proprietary BioRetain® processing method to enhance growth factors and tissue structure. The company's manufacturing is FDA registered and AATB accredited, with products like VENDAJE® at its Pompano Beach, Florida site.